23andMe Holding Co.

Ownership Transactions Reported by 25 Insiders

Symbol
ME on Nasdaq
Industry
Pharmaceutical Preparations
Location
223 N. Mathilda Ave., Sunnyvale, CA

Insiders trading volume in the past year

23andMe Holding Co. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Paul D. Johnson VP, General Manager-Consumer $939K Feb 9, 2022
Evan Lovell Director $879K Aug 11, 2022
Kathy L. Hibbs Chief Administrative Officer $665K -$19K -2.78% May 20, 2024
Rice Valerie Md Montgomery Director $404K Aug 26, 2024
Sandra Hernandez Director $402K Aug 26, 2024
Patrick Chung Director $388K Aug 26, 2024
Roelof Botha Director $382K Aug 26, 2024
Peter J. Taylor Director $328K Aug 26, 2024
Neal Mohan Director $302K Aug 26, 2024
Richard H. Scheller Director $299K Aug 26, 2024
Joseph Selsavage Chief Financial & Actng Ofcr $264K Feb 20, 2025
Steven Lemon Vice President, Engineering $247K Feb 9, 2022
William G. Richards Head of Therapeutics Discovery $204K Aug 20, 2024
Kenneth J. Hillan Chief Therapeutics Officer $159K Jun 5, 2023
Steven J. Schoch Chief Financial Officer $151K Aug 20, 2022
Tracy Keim VP, Consumer Marketing & Brand $89.4K Feb 9, 2022
Frederick Kohler Vice President, People $51.1K Feb 9, 2022
Andre J. Fernandez Director Oct 28, 2024
Jim Frankola Director Oct 28, 2024
Mark Jensen Director Oct 28, 2024
Thomas Walper Director Mar 23, 2025
Sc Us (Ttgp), Ltd. 10%+ Owner Jun 16, 2021
Matthew Kvarda Chief Restructuring Officer Mar 23, 2025
Anne Wojcicki Chief Executive Officer, Director, 10%+ Owner Sep 15, 2023
GSK plc 10%+ Owner Jun 16, 2021

Recent Insider Transactions by Companies or Individuals for 23andMe Holding Co.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.